Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Fig. 1

Patient disposition of all screened patients. IRRC, independent radiological review committee. Note Pathological diagnosis was done by study site pathologists for study enrolment and patient eligibility was determined by site investigators. Central pathology review was conducted retrospectively upon patient consent. Retrospectively pathological confirmation per central pathology review was not available in 13 patients, leaving 89 patients entering FAS

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us